| Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 … CH Geisler, A Kolstad, A Laurell, NS Andersen, LB Pedersen, ... Blood, The Journal of the American Society of Hematology 112 (7), 2687-2693, 2008 | 757 | 2008 |
| Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study M Dreyling, W Jurczak, M Jerkeman, RS Silva, C Rusconi, M Trneny, ... The Lancet 387 (10020), 770-778, 2016 | 510 | 2016 |
| Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆ M Dreyling, M Ghielmini, S Rule, G Salles, M Ladetto, SH Tonino, ... Annals of Oncology 32 (3), 298-308, 2021 | 477 | 2021 |
| Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry F Ellin, J Landström, M Jerkeman, T Relander Blood, The Journal of the American Society of Hematology 124 (10), 1570-1577, 2014 | 375 | 2014 |
| TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy CW Eskelund, C Dahl, JW Hansen, M Westman, A Kolstad, LB Pedersen, ... Blood, The Journal of the American Society of Hematology 130 (17), 1903-1910, 2017 | 363 | 2017 |
| Nordic MCL 2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem‐cell support … CH Geisler, A Kolstad, A Laurell, M Jerkeman, R Räty, NS Andersen, ... British journal of haematology 158 (3), 355-362, 2012 | 326 | 2012 |
| Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis M Berglund, U Thunberg, RM Amini, M Book, G Roos, M Erlanson, ... Modern pathology 18 (8), 1113-1120, 2005 | 306 | 2005 |
| Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Dreyling, E Campo, O Hermine, M Jerkeman, S Le Gouill, S Rule, ... Annals of Oncology 28, iv62-iv71, 2017 | 300 | 2017 |
| Nuclear expression of the non–B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma S Ek, M Dictor, M Jerkeman, K Jirström, CAK Borrebaeck Blood, The Journal of the American Society of Hematology 111 (2), 800-805, 2008 | 248 | 2008 |
| 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL 2): prolonged remissions without survival plateau CW Eskelund, A Kolstad, M Jerkeman, R Räty, A Laurell, S Eloranta, ... British journal of haematology 175 (3), 410-418, 2016 | 220 | 2016 |
| The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line … CH Geisler, A Kolstad, A Laurell, R Räty, M Jerkeman, M Eriksson, ... Blood, The Journal of the American Society of Hematology 115 (8), 1530-1533, 2010 | 212 | 2010 |
| Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP H Nyman, M Jerkeman, ML Karjalainen-Lindsberg, AH Banham, S Leppä Modern pathology 22 (8), 1094-1101, 2009 | 170 | 2009 |
| Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma NS Andersen, LB Pedersen, A Laurell, E Elonen, A Kolstad, AM Boesen, ... Journal of Clinical Oncology 27 (26), 4365-4370, 2009 | 159 | 2009 |
| Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study A Abrahamsson, A Albertsson-Lindblad, PN Brown, ... Blood, The Journal of the American Society of Hematology 124 (8), 1288-1295, 2014 | 152 | 2014 |
| SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a Nordic Lymphoma Group study L Nordström, S Sernbo, P Eden, K Grønbaek, A Kolstad, R Räty, ... British journal of haematology 166 (1), 98-108, 2014 | 151 | 2014 |
| Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma SH Walsh, M Thorsélius, A Johnson, O Söderberg, M Jerkeman, ... Blood, The Journal of the American Society of Hematology 101 (10), 4047-4054, 2003 | 148 | 2003 |
| Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo A Roghanian, I Teige, L Mårtensson, KL Cox, M Kovacek, A Ljungars, ... Cancer cell 27 (4), 473-488, 2015 | 147 | 2015 |
| Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial M Jerkeman, CW Eskelund, M Hutchings, R Räty, KF Wader, A Laurell, ... The Lancet Haematology 5 (3), e109-e116, 2018 | 140 | 2018 |
| KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study S Ferrero, D Rossi, A Rinaldi, A Bruscaggin, V Spina, CW Eskelund, ... Haematologica 105 (6), 1604, 2020 | 130 | 2020 |
| Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study J Linderoth, M Jerkeman, E Cavallin-Ståhl, S Kvaløy, E Torlakovic Clinical Cancer Research 9 (2), 722-728, 2003 | 127 | 2003 |
Arne KolstadMD PhD, Department of Oncology, Oslo University HospitalVerified email at ous-hf.no
